OncoMatch/Head & Neck Cancer (HNSCC)/EGFR
Head & Neck Cancer (HNSCC)EGFR Clinical Trials
EGFR overexpression is near-universal in HNSCC, and cetuximab — an anti-EGFR monoclonal antibody — is an approved treatment option in recurrent/metastatic disease and as part of concurrent chemoradiation. EGFR gene amplification occurs in ~10–15% of cases. Trials investigate novel EGFR-directed ADCs (ABT-165), bispecific antibodies (EGFR × MET, EGFR × PD-L1), and cetuximab combinations with checkpoint immunotherapy for EGFR-amplified or -overexpressing HNSCC.
Top recruiting EGFR Head & Neck Cancer (HNSCC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
Fudan University
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience, Inc.
Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
Sichuan Cancer Hospital and Research Institute
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
More EGFR Head & Neck Cancer (HNSCC) trials
Browse other molecular targets with active Head & Neck Cancer (HNSCC) trials.